Biopharmaceutical News and Research

RSS

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.

18 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.

11 Apr 2011

PAREXEL's QbD approaches can help pharma companies maximize product quality, safety

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and the Parenteral Drug Association today announced the publication of Quality by Design: Putting Theory into Practice, written to help companies maximize product quality and safety. As increasing regulatory pressure is being placed on biopharmaceutical companies to be accountable for Quality Systems, the book serves as a definitive source on the interpretation and implementation of Quality by Design approaches.

From Parexel 11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.

8 Apr 2011

Idenix begins underwritten registered public offering of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of shares of its common stock. All of these shares are being sold by Idenix.

8 Apr 2011

Aptiv Solutions creates Adaptive Clinical Trials Innovation Center

Aptiv Solutions, a global biopharmaceutical and medical device development services company, announced today the creation of an Adaptive Clinical Trials Innovation Center.

6 Apr 2011

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Shire plc, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the Southern District of New York against Watson Pharmaceuticals, Inc. and its subsidiaries Watson Laboratories, Inc.-Florida, Watson Pharma, Inc., Andrx Corporation, and Andrx Pharmaceuticals, L.L.C. for infringement of Shire's U.S. Reissue Patent No. RE 41,148, U.S. Reissue Patent No. RE 42,096 and U.S. Patent No. 6,913,768 and also for breach of contract.

6 Apr 2011

Thermo Fisher completes Athena and Lancaster sales for $940 million

Thermo Fisher Scientific Inc., the world leader in serving science, has completed the previously announced sales of its two laboratory-testing services businesses, Athena Diagnostics and Lancaster Laboratories, in two separate transactions, resulting in total proceeds of $940 million.

From Thermo Fisher Scientific Inc. 5 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

Pfizer reports details of financial interactions with the medical and scientific community

Pfizer Inc. today released a report detailing the company's financial interactions with health care professionals and researchers in 2010.

1 Apr 2011

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluating OMS103HP in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery.

1 Apr 2011

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Nile's post-acute development program for cenderitide, which has the goal of reducing cardiovascular mortality and cardiovascular re-hospitalization in the post-acute period in patients with acute decompensated heart failure.

31 Mar 2011

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010.

31 Mar 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies, announced today that it will present preclinical data in two poster presentations at the 102nd American Association for Cancer Research annual meeting in Orlando, FL during April 2-6, 2011.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Biopharmaceutical News and Research

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Major pharmaceutical company, Access sign deal for RNAi therapeutics

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

PAREXEL's QbD approaches can help pharma companies maximize product quality, safety

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix begins underwritten registered public offering of common stock

Aptiv Solutions creates Adaptive Clinical Trials Innovation Center

Shire files lawsuit against Watson over ADDERALL XR patent infringement

Thermo Fisher completes Athena and Lancaster sales for $940 million

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

NeoStem revenues increase 13% for the year ended December 31, 2010

ACADIA extends collaboration agreement with Allergan for drug discovery platform

Pfizer reports details of financial interactions with the medical and scientific community

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Sinovac reports fourth quarter net sales of $9.1 million

RXi Pharmaceuticals to acquire Apthera

Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News